This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 734694
Download Presentation The PPT/PDF document "Dual Antiretroviral Therapy" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Dual Antiretroviral TherapySlide2Slide3
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide4
Current Paradigm: Triple Therapy Is Very EffectiveSlide5
Good Adherence With Single-Tablet Triple-Therapy RegimensSlide6
Recent Advances: Agents and RegimensSlide7
From Triple Therapy to Dual TherapySlide8
From Triple Therapy to Dual Therapy
Potential AdvantagesSlide9
From Triple Therapy to Dual Therapy
Potential Advantages (cont)Slide10
Dual Therapy: Some Early Attempts That Fell Short
Maintenance TreatmentSlide11
Dual Therapy: Some Early Attempts That Fell Short
Initial TreatmentSlide12
Dual Therapy Success With PI/b + 3TC Regimens
Initial TreatmentSlide13
Dual Therapy Success With PI/b + 3TC Regimens
Initial TreatmentSlide14
From PI/b-Based to Integrase Inhibitor-Based RegimensSlide15
Integrase Inhibitor-Based 2-Drug Regimens
DTG + 3TC in Treatment-Naive PatientsSlide16
Integrase-Based 2-Drug Regimens
DTG + 3TC in Treatment-Experienced PatientsSlide17
Long-Acting Injectables: CAB/RPV StudiesSlide18
DTG/RPV: First 2-Drug STR
SWORD 1 and SWORD 2Slide19
SWORD: Tolerability and SafetySlide20
DTG/RPV: IndicationSlide21
Patient Selection for DTG/RPVSlide22
Concluding RemarksSlide23